|
Variables
|
Univariate analysis
|
Multivariate analysis
|
|---|
|
HR
|
[95% CI]
|
p-value
|
HR
|
[95% CI]
|
p-value
|
|---|
|
Regimen
|
|
FP (vs. F)
|
0.56
|
[0.39–0.82]
|
< 0.01
|
0.47
|
[0.31–0.72]
|
< 0.01
|
|
Age
|
|
≥65 (vs. < 65)
|
0.80
|
[0.55–1.17]
|
0.25
| | | |
|
Sex
|
|
Female (vs. male)
|
1.05
|
[0.72–1.54]
|
0.78
| | | |
|
PS
|
|
2–4 (vs. 0–1)
|
1.22
|
[0.83–1.79]
|
0.32
|
0.95
|
[0.62–1.48]
|
0.83
|
|
Histology
|
|
Intestinal (vs. diffuse)
|
0.71
|
[0.43–1.19]
|
0.19
|
0.70
|
[0.41–1.19]
|
0.18
|
|
Unknown (vs. diffuse)
|
NA
| |
NA
|
NA
| |
NA
|
|
Disease status
|
|
Recurrent (vs. advanced)
|
0.58
|
[0.25–1.32]
|
0.19
|
0.86
|
[0.36–2.10]
|
0.75
|
|
Primary site
|
|
GEJ (vs. stomach)
|
0.98
|
[0.40–2.41]
|
0.96
| | | |
|
No. of metastatic sites
|
|
≥3 (vs. 1–2)
|
1.43
|
[0.92–2.23]
|
0.11
|
1.64
|
[0.97–2.76]
|
0.07
|
|
Target lesion
|
|
Absence (vs. presence)
|
0.95
|
[0.65–1.38]
|
0.78
| | | |
|
Subtype of SPM
|
|
Inadequate oral intake (vs. massive ascites)
|
0.81
|
[0.52–1.29]
|
0.38
|
0.58
|
[0.33–1.00]
|
0.05
|
|
Both (vs. massive ascites)
|
1.09
|
[0.69–1.71]
|
0.71
|
0.76
|
[0.44–1.29]
|
0.31
|
|
Serum albumin level
|
|
< 3.1 g/ml (vs. > 3.1 g/ml)
|
1.42
|
[0.97–2.07]
|
0.07
|
1.43
|
[0.94–2.17]
|
0.09
|
- AGC advanced gastric cancer, CI confidence interval, ECOG PS Eastern Cooperative Oncology Group performance status, GEJ gastroesophageal junction, HR hazard ratio, NA not assessed, OS overall survival, SPM severe peritoneal metastasis
